Literature DB >> 11604163

Fusion of C3d molecule with bovine rotavirus VP7 or bovine herpesvirus type 1 glycoprotein D inhibits immune responses following DNA immunization.

S Suradhat1, R P Braun, P J Lewis, L A Babiuk, S van Drunen Littel-van den Hurk, P J Griebel, M E Baca-Estrada.   

Abstract

The binding of the complement C3d molecule with receptors on B cells and/or follicular dendritic cells (FDCs) influences the induction of humoral immune responses. For example, C3d fused to an antigen has been shown to have a strong adjuvant effect on antibody production. We investigated the possibility that co-expression of antigen and C3d as a fusion protein could enhance antigen-specific immune responses, following plasmid immunization. One or two copies of murine C3d-cDNA, C3d or (C3d)(2), respectively, were cloned together with bovine rotavirus (BRV) VP7 or bovine herpesvirus type 1 (BHV-1) glycoprotein D (gD) genes. All constructs contained a signal peptide that resulted in the secretion of the expressed proteins. In vitro, the characterization of the chimeric proteins indicated that both VP7 and gD retained their antigenicity and the C3d remained biologically active. However, immunization with plasmids encoding VP7-C3d chimeras did not enhance rotavirus-specific antibody responses and the frequency of BRV-specific IFN-gamma secreting cells in the spleens were significantly lower in mice immunized with pVP7-(C3d)(2) when compared with mice immunized with plasmid encoding VP7. The same pattern of immune responses was observed for plasmids encoding gD-C3d. Both gD-specific antibody responses and the frequency of gD-specific IFN-gamma secreting cells were significantly lower in mice immunized with plasmid expressing gD-C3d chimeras when compared with mice immunized with plasmid encoding gD alone. These results indicate that co-expression of C3d with an antigen actually inhibit both humoral and cell-mediated antigen-specific immune responses.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11604163     DOI: 10.1016/s0165-2427(01)00369-5

Source DB:  PubMed          Journal:  Vet Immunol Immunopathol        ISSN: 0165-2427            Impact factor:   2.046


  11 in total

1.  Contribution of C3d-P28 repeats to enhancement of immune responses against HBV-preS2/S induced by gene immunization.

Authors:  Li-Xin Wang; Wei Xu; Qing-Dong Guan; Yi-Wei Chu; Ying Wang; Si-Dong Xiong
Journal:  World J Gastroenterol       Date:  2004-07-15       Impact factor: 5.742

Review 2.  Complement-mediated activation of the adaptive immune responses: role of C3d in linking the innate and adaptive immunity.

Authors:  Franklin R Toapanta; Ted M Ross
Journal:  Immunol Res       Date:  2006       Impact factor: 2.829

3.  A vaccine directed to B cells and produced by cell-free protein synthesis generates potent antilymphoma immunity.

Authors:  Patrick P Ng; Ming Jia; Kedar G Patel; Joshua D Brody; James R Swartz; Shoshana Levy; Ronald Levy
Journal:  Proc Natl Acad Sci U S A       Date:  2012-08-08       Impact factor: 11.205

4.  DENV-2 subunit proteins fused to CR2 receptor-binding domain (P28)-induces specific and neutralizing antibodies to the Dengue virus in mice.

Authors:  Jazmín García-Machorro; Moisés López-González; Olivia Barrios-Rojas; Cynthia Fernández-Pomares; Claudia Sandoval-Montes; Leopoldo Santos-Argumedo; Nicolás Villegas-Sepúlveda; Benito Gutiérrez-Castañeda; Leticia Cedillo-Barrón
Journal:  Hum Vaccin Immunother       Date:  2013-07-23       Impact factor: 3.452

5.  Fusion to chicken C3d enhances the immunogenicity of the M2 protein of avian influenza virus.

Authors:  Zhenhua Zhang; Yongqing Li; Shufang Xu; Fuyong Chen; Li Zhang; Beiyu Jiang; Xiaoling Chen
Journal:  Virol J       Date:  2010-05-09       Impact factor: 4.099

6.  Fusion to C3d enhances the immunogenicity of the E2 glycoprotein of type 2 bovine viral diarrhea virus.

Authors:  Lingshu Wang; J Oriol Sunyer; Leonard J Bello
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

7.  Enhancement of antibodies to the human immunodeficiency virus type 1 envelope by using the molecular adjuvant C3d.

Authors:  Thomas D Green; David C Montefiori; Ted M Ross
Journal:  J Virol       Date:  2003-02       Impact factor: 5.103

8.  Complement C3d conjugation to anthrax protective antigen promotes a rapid, sustained, and protective antibody response.

Authors:  Ravi V Kolla; Suresh Chintalapati; Mojgan Sabet; Eugenio Santelli; Robert C Liddington; Michael David; Joshua Fierer; Donald Guiney; Robert C Rickert
Journal:  PLoS One       Date:  2007-10-17       Impact factor: 3.240

9.  A novel C3d-containing oligomeric vaccine provides insight into the viability of testing human C3d-based vaccines in mice.

Authors:  Yong-Gang He; Isabel Y Pappworth; Andreas Rossbach; Joshua Paulin; Tarirai Mavimba; Christine Hayes; Liudmila Kulik; V Michael Holers; Andrew M Knight; Kevin J Marchbank
Journal:  Immunobiology       Date:  2017-10-04       Impact factor: 3.144

10.  Utilization of Staphylococcal Immune Evasion Protein Sbi as a Novel Vaccine Adjuvant.

Authors:  Yi Yang; Catherine R Back; Melissa A Gräwert; Ayla A Wahid; Harriet Denton; Rebecca Kildani; Joshua Paulin; Kristin Wörner; Wolgang Kaiser; Dmitri I Svergun; Asel Sartbaeva; Andrew G Watts; Kevin J Marchbank; Jean M H van den Elsen
Journal:  Front Immunol       Date:  2019-01-11       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.